Emerging Technologies for the Treatment of Structural Heart Disease
Mark J. Russo, MD, MS
Director, Endovascular CardioAortic Therapies
Mark J. Russo, MD, MS, specializes in high-risk cardiothoracic surgery, including lung and heart transplantation and aortic surgery. He has participated in more than 300 successful organ transplants and has a special interest in offering the benefits of transplant to patients previously considered too high-risk for transplantation.
Dr. Russo also focuses on complex and reoperative aortic surgery. He uses leading-edge technologies (including minimally invasive endovascular and hybrid approaches, stentless valves, biologic composite grafts, valve-sparing aortic roots, and advanced cardiopulmonary perfusion techniques) to minimize the risks of cardiothoracic surgery.
An active researcher, Dr. Russo has authored more than 60 published papers focused on improving clinical outcomes for patients. He has a particular interest in the clinical and economic evaluation of rapidly evolving device technologies for treating cardiac disease, as well as strategies to maximize the benefits of transplantation. Dr. Russo serves as an investigator for a number of multi-institution clinical trials, including the National Heart, Lung, and Blood Institute’s Cardiothoracic Surgery Trials Network and the International Registry of Acute Aortic Dissections. For his work, Dr. Russo has received awards from professional and research organizations, including the Society of Thoracic Surgeons, European Society of Cardiology, Association of American Medical Colleges, American Heart Association, and National Institutes of Health.
Clinical Interests
- Lung transplantation
- Aortic surgery
- Endovascular and hybrid surgery
Atman P. Shah, MD
Director, Transcatheter Valve Therapies
Working at the University of Chicago has allowed Dr. Atman P. Shah to blend his clinical and translational research interests. Dr. Shah is currently studying the role of inflammatory cytokines and progenitor cells in a large animal model of ischemic arrest. Studying what influences survival in animals who have suffered cardiac arrest may directly translate into implementing therapies that save the lives of thousands of patients a year who suffer from cardiac arrest. This blends very well with his studies of implementing systems of care that deliver the best possible care to patients who suffer from acute myocardial infarctions.
Additionally, he is researching the role of intravascular ultrasound during angioplasty procedures in patients who are suffering from acute myocardial infarction, as well as different novel therapies that can help save heart muscle during a heart attack. He is also the primary investigator on a clinical study that is investigating the role of peripheral arterial disease in men who have erectile dysfunction and the primary investigator of a trial that is studying the clinical safety of a same-day discharge program for patients undergoing angioplasty as an outpatient.
Other interests include treatment of coronary artery disease using the latest techniques, including angioplasty, stents, atherectomy, and thrombectomy; utilization of minimally invasive techniques to treat carotid and peripheral arterial disease; treatment of structural heart disease, including the percutaneous repair of atrial and ventricular septal defects, coronary and peripheral fistulae, and valvular stenosis; and treatment of survivors of cardiac arrest with aggressive revascularization and hypothermia.
Clinical Interests
- Coronary artery disease
- Ventricular septal defects
- Minimally invasive surgery
- Coronary and peripheral fistulae
- Carotid artery disease
- Valvular stenosis
- Peripheral artery disease
- Atrial septal defects
Additional faculty bios coming soon.
Faculty Disclosure
It is the policy of the University of Chicago to ensure balance, independence, objectivity, and scientific rigor in all its individually sponsored or jointly sponsored educational activities. All individuals who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the education activity. Mechanisms to ensure that presentations are free from commercial bias are in place. Faculty will also disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Full disclosure of this information will be published in the activity material.